US COST-EFFECTIVENESS OF LENACAPAVIR PLUS OPTIMIZED BACKGROUND REGIMEN VERSUS OTHER TREATMENTS FOR MULTI-DRUG RESISTANT HIV

被引：0
|
作者：
Vardanega, V. [1 ]
New, E. [1 ]
Mezzio, D. [2 ]
Eddowes, L. A. [1 ]
机构：
[1] Costello Med, London, England
[2] Gilead Sci, Foster City, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE472
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [1] LONG-TERM OUTCOMES OF LENACAPAVIR PLUS OPTIMIZED BACKGROUND REGIMEN VERSUS OTHER TREATMENTS FOR MULTI-DRUG RESISTANT HIV VIA A COST-EFFECTIVENESS MODEL
    Vardanega, V.
    Rawlinson, W.
    Francis-Graham, S.
    Mezzio, D.
    Eddowes, L. A.
    VALUE IN HEALTH, 2022, 25 (07) : S379 - S379
  • [2] Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus
    Chatzidaki, Iro
    Curteis, Tristan
    Luedke, Hannah
    Mezzio, Dylan J.
    Rhee, Martin S.
    McArthur, Eve
    Eddowes, Lucy A.
    VALUE IN HEALTH, 2023, 26 (06) : 810 - 822
  • [3] US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance
    Vardanega, Vittoria
    New, Emma
    Mezzio, Dylan
    Eddowes, Lucy A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (09): : 1001 - 1012
  • [4] Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia: a comment
    Davoudi-Monfared, Effat
    Taghizadeh-Ghehi, Maryam
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (03) : 621 - 622
  • [5] Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia: a comment
    Effat Davoudi-Monfared
    Maryam Taghizadeh-Ghehi
    International Journal of Clinical Pharmacy, 2019, 41 : 621 - 622
  • [6] An Analysis of The Cost of New Treatments for Multi-Drug Resistant Tuberculosis
    O'Flaherty, Niamh
    Ottewill, Ciara
    McNally, Emma
    Dolan, Lorraine
    O'Reilly, Aoife
    McLaughlin, Anne-Marie
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 : S156 - S157
  • [7] Cost effectiveness of treating multi-drug resistant tuberculosis by adding DeltybaTM to background regimens in Germany
    Diel, Roland
    Hittel, Norbert
    Schaberg, Tom
    RESPIRATORY MEDICINE, 2015, 109 (05) : 632 - 641
  • [8] Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia
    Cara, Abdul Karim Suleman
    Zaidi, Syed Tabish Razi
    Suleman, Fatima
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (05) : 1051 - 1058
  • [9] Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia
    Abdul Karim Suleman Cara
    Syed Tabish Razi Zaidi
    Fatima Suleman
    International Journal of Clinical Pharmacy, 2018, 40 : 1051 - 1058
  • [10] Long-acting lenacapavir in people with multi-drug resistant HIV-1: week 52 results
    Ogbuagu, Onyema
    Segal-Maurer, Sorana
    Brinson, Cynthia
    Chetchotisakd, Ploenchan
    McGowan, Joseph P.
    Workowski, Kimberly
    Wang, Hui
    Margot, Nicolas
    Dvory-Sobol, Hadas
    Rhee, Martin S.
    Baeten, Jared
    Kabagambe, Samm
    Molina, Jean-Michel
    HIV MEDICINE, 2022, 23 : 26 - 27
12345